Advertisement

Topics

US FDA accepts Seattle Genetics' sBLA for Adcetris in CTCL and grants priority review status

08:59 EDT 18 Aug 2017 | PharmaBiz

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the phase 3 ALCANZA

Original Article: US FDA accepts Seattle Genetics' sBLA for Adcetris in CTCL and grants priority review status

NEXT ARTICLE

More From BioPortfolio on "US FDA accepts Seattle Genetics' sBLA for Adcetris in CTCL and grants priority review status"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...